Dopamine D3 and D4 receptor antagonists: Synthesis and structure- activity relationships of (S)-(+)-N-(1-benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl)amino]-2-methoxybenzamide (YM-43611) and related compounds

Journal of Medicinal Chemistry

Volumn 39, Issue 14, 1996, Pages 2764-2772

  Ohmori, Junya ^a   Maeno, Kyoichi ^a   Hidaka, Kazuyuki ^a   Nakato, Kazuhiro ^a   Matsumoto, Mitsuyuki ^a   Tada, Shoko ^a   Hattori, Hanae ^a   Sakamoto, Shuichi ^a   Tsukamoto, Shin Ichi ^a   Usuda, Shinji ^a   Mase, Toshiyasu ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 4 RECEPTOR; N (1 BENZYL 3 PYRROLIDINYL) 5 CHLORO 4 CYCLOPROPYLCARBOXAMIDO 2 METHOXYBENZAMIDE; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DRD3 PROTEIN, HUMAN; DRD3 PROTEIN, MOUSE; DRD3 PROTEIN, RAT; DRD4 PROTEIN, HUMAN; DRD4 PROTEIN, MOUSE; DRD4 PROTEIN, RAT; N (1 BENZYL 3 PYRROLIDINYL) 5 CHLORO 4 ((CYCLOPROPYLCARBONYL)AMINO) 2 METHOXYBENZAMIDE; N-(1-BENZYL-3-PYRROLIDINYL)-5-CHLORO-4-((CYCLOPROPYLCARBONYL)AMINO)-2-METHOXYBENZAMIDE; NEUROLEPTIC AGENT;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; DOPAMINERGIC TRANSMISSION; ENANTIOMER; MOUSE; NEUROTRANSMISSION; NONHUMAN; RECEPTOR BINDING; SEROTONIN BRAIN LEVEL; ANIMAL; CHO CELL; DRUG ANTAGONISM; DRUG EFFECT; HAMSTER; HUMAN; INSTITUTE FOR CANCER RESEARCH MOUSE; MALE; MOTOR ACTIVITY; RAT; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZAMIDES; CHO CELLS; CRICETINAE; DOPAMINE ANTAGONISTS; HUMANS; MALE; MICE; MICE, INBRED ICR; MOTOR ACTIVITY; RATS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RECEPTORS, DOPAMINE D4; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 8944252333     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9601720     Document Type: Article

References (38)

1. Crow, T. J. Molecular Pathology of Schizophrenia: More Than One Disease Process? Br. Med. J. 1980, 280, 66.
2. Tarsy, D. Neuroleptic-Induced Extrapyramidal Reactions; Classification, Description and Diagnosis. Clin. Neuropharmacol. 1983, 6, S9-S26.
3. Creese, I.; Burt, D. R.; Snyder, S. H. Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs. Science 1976, 792, 481-483.
4. Seeman, P.; Lee T.; Chau-Wong, M.; Wong, K.; Antipsychotic Drug Dose and Neuroleptic/Dopamine Receptors. Nature 1976, 261, 717-719.
5. 2-Dopamine Receptor Occupancy in Relation to Antipsychotic Drug Effects: A Double-Blind PET Study of Schizophrenic Patients. Biol. Psychiatry 1991, 33, 227-235.
6. 3) as a Target for Neuroleptics. Nature 1990, 347, 146-151.
7. 4 Receptor with High Affinity for the Antipsychotic Clozapine. Nature 1991, 350, 610-614.
8. 1. Nature 1991, 350, 614-619.
9. 2 Receptor m RNA. Brain Res. 1991, 564, 203-219.
10. 4. Neuropsychopharmacology 1992, 7, 261-284.
11. 4 Receptor (D4DR) Exon III Polymorphism Associated with the Human Personality Trait of Novelty Seeking. Nature: Genet. 1996, 12, 78.
12. 4 Receptors Elevated in Schizophrenia. Nature 1993, 365, 441-445.
13. 2 receptor selectivity of dopamine receptor antagonists: Possible Therapeutic Implications. Eur. J. Pharmacol. 1993, 236, 483-486.
14. Wagstaff, A. J.; Bryson, H. M.; Clozapine: A Review of Its Pharmacological Properties and Therapeutic Use in Patients with Schizophrenia Who Are Unresponsive to or Intolerant of Classical Antipsychotic Agents. CNS Drugs 1995, 4, 370-400.
15. Pickar, D.; Hsiao, J. K. Clozapine Treatment of Schizophrenia. J. Am. Med. Assoc. 1995, 274, 981-983.
16. Meltzer, H. Y. The Importance of Serotonin-Dopamine Interactions in the Action of Clozapine. Br. J. Psychiatry 1992, 760 (Suppl. 17), 22-29.
17. 3-Receptor: A Post Synaptic Receptor Inhibitory on Rat Locomotor Activity. J. Neural Transm.: Gen. Sect. 1993, 347, 146-151.
18. Strange, P. G. Interesting Times for Dopamine Receptors. Trends Neurosci. 1991, 14, 43-45.
19. Taubes, G. Will New Dopamine Receptors Offer a Key to Schizophrenia? Science 1994, 265, 1034-1035.
20. 4 Dopamine Receptors Determined in Transfected Cell Lines. Clin. Neuropharmacol. 1995, 18 (Suppl. 1), S25-S33.
21. 3 Receptors. Bioorg. Med. Chem. Lett. 1995, 5, 219-222.
22. 2 Receptor Elicits Prolactin Secretion and Catalepsy. J. Pharmacol. Exp. Ther. 1995, 275, 885-898.
23. Sautel, F.; Griffon, N.; Sokoloff, P.; Schwartz, J.-C.; Launay, C.; Simon, P.; Costentin, J.; Schoenfelder, A.; Garrido, F.; Mann, A.; Wermuth, C. G. Nafadotride, a Potent Preferential Dopamine D3 Receptor Antagonist, Activates Locomotion in Rodents. J. Pharmacol. Exp. Ther. 1995, 275, 1239-1246.
24. Thurkauf, A.; Yuan, J.; Chen, X.; Wasley, J. W. F.; Meade, R.; Woodruff, Huston, K.; Ross, P. C. 1-Phenyl-3-(aminoethyl)-pyrroles as Potential Antipsychotic Agents. Synthesis and dopamine Receptor Binding. J. Med. Chem. 1995, 38, 4950-4952.
25. Sokoloff, P.; Schwartz, J.-C. Novel Dopamine Receptors Half a Decade Later. Trends Pharmacol. Sci. 1995, 16, 270-275.
26. Seabrook, G. R.; Patel, S.; Hutson, P. H.; Ragan, C. I.; Bristow, L. J. Functional Relevance of Dopamine Receptors. Trends Pharmacol. Sci. 1995, 16, 406-407.
27. Iwanami, S.; Takashima, M.; Hirata, Y.; Hasegawa, O; Usuda, S. Synthesis and Neuroleptic Activity of Benzamides. cis-N-(1-Benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-(methylamino) benzamide and Related Compounds. J. Med. Chem. 1981, 24, 1224-1230.
28. 4 Receptor Antagonist. Poster Presentation at the ACS National Meeting, Chicago, IL, August 1995; MEDI 134.
29. 4 Receptors. Br. J. Pharmacol. 1996, 117, 1625-1632.
30. 4 antagonist, YM-43611. Jpn. J. Psychopharmacol. 1995, 15, 490.
31. Compound 12 has been synthesized by an alternative procedure; see: Ehrenkaufer, R. L.; Scripko, J. G.; Hoffman, P. L. A Convenient Synthesis of Methyl 4-amino-5-chloro-2-methoxy-benzoate. Org. Prep. Proced. Int. 1992, 24, 64-66.
32. Murakami, M.; Inukai, N.; Koda, A.; Nakano, K. An Improved Synthesis of Metoclopramide. Chem. Pharm. Bull. Jpn. 1971, 19, 1696-1699.
33. Shioiri, T.; Ninomiya, K.; Yamada, S. Diphenylphosphoryl Azide. A New Convenient Reagent for a Modified Curtius Reaction and for the Peptide Synthesis. J. Am. Chem. Soc. 1972, 94, 6203-6205.
34. Costall, B.; Naylor, R. J.; Nohria, V. Climbing Behavior Induced by Apomorphine in Mice: A Potencial Model for the Detection of Neuroleptic Activity. Eur. J. Pharmacol. 1978, 50, 39-59.
35. Hansch, C.; Leo, A.; Unger S. H.; Kim, K. H.; Nikaitani, D.; Lien, E. J. "Aromatic" Substituent Constants for Structure-Activity Correlations. J. Med. Chem. 1973, 16, 1207-1216.
36. 4 Receptors. Neurosci. Lett. 1995, 186, 145-148.
37. Rognan, D.; Sokoloff, P.; Mann, A.; Martres, M.-P.; Schwartz, J.-C.; Costentin, J.; Wermuth, C.-G. Eur. J. Pharmacol. Mol. Pharmacol. Sect. 1990, 189, 59-70.
38. Terai, M.; Usuda, S.; Kuroiwa, I.; Noshiro, O.; Maeno, H. Selective Binding of YM-09151-2, a New Potent Neuroleptic, to Du-Dopaminergic Receptors. Jpn. J. Pharmacol. 1983, 33, 749-755.